Galectin 1 rescues microvascular alterations in Alzheimer’s disease in in vivo and in vitro models involving endoplasmic reticulum stress pathways

PRESA J; POMILIO C; GORI S; MATZKIN E; ALAIMO A; SOIZA-RELLY M; PÉREZ OE ; RAMHORST R; BEAUQUIS J; RABINOVICH G; SARAVIA F

Mar del Plata

Congreso; LXVIII Reunión Científica Anual de la SAIC.; 2023

Sociedad Argentina de Investigación Clínica

As a multifactorial pathology, Alzheimer’s disease (AD)exhibits marked vascular alterations that correlate withdisease progression. The immense impact of AD requiresnew and effective therapeutics. Galectins, a family ofproteins that bind to outer membrane oligosaccharides,trigger various cell responses involving immune and vascularmodulation. Galectin-1 (Gal1) may have beneficialeffects on neurological disorders. We treated PDAPPJ20(Tg) mice -an AD model- with Gal1(3 weekly i.p. injectionsof 100 ug/dose, 9 injections). Tg-Gal1 mice showeda 50% reduction in perivascular Aβ compared to vehicle-treated littermates (Tg-Veh) (p